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 RT end 
1 
month 
4 
months 
8 
months 
14 
months 
20 
months 
26 
months 
32 
months 
38 
months 
N of 
observed 
patients 
350 214 255 212 146 91 53 22 7 
No ADT 
[%] 42.6 64.8 72.7 78.1 85.7 84.4 96.2 100 100 
GI 0 [%] 90.3 91.0 93.9 93.3 97.8 96.1 100 100 100 
GI 1 [%] 9.1 6.6 4.9 6.2 2.2 3.9 - - - 
GI 2 [%] 0.6 1.9 0.8 0.5 - - - - - 
GI 3 [%] - 0.5 0.4 - - - - - - 
GU 0 [%] 77.1 70.8 89.4 95.9 87.3 97.4 98.1 95.2 100 
GU 1 [%] 16.3 25.0 8.2 3.6 9.7 2.6 1.9 4.8 - 
GU 2 [%] 6.0 3.8 2.4 0.5 3.0 - - - - 
GU 3 [%] 0.6 0.4 - - - - - - - 
PSA 
range 
[ng/ml] 
0.008-
20.4 
0.003-
16.3 
0.002-
8.2 0.0-6.4 
0.002-
3.5 
0.04-
2.2 0.0-3.3 
0.02-
3.8 
0.003-
0.6 
PSA 
mean 3.7 1.9 1.1 0.7 0.5 0.4 0.4 0.5 0.3 
PSA 
median 2.2 1.0 0.3 0.3 0.2 0.2 0.2 0.1 0.2 
 
Conclusion: The results obtained permit us to form the 
conclusion that CK based radioablation of low and 
intermediate risk PC patients is an effective treatment 
modality enabling OTT shrinkage and giving a very low 
percentage of adverse effects. 
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Purpose or Objective: Recent understanding of radiobiology 
for prostate cancer suggested hypofractionation might 
achieve a higher therapeutic benefit. Stereotactic body 
radiation therapy (SBRT) is able to delivery high dose per 
fraction precisely. SBRT for prostate cancer might escalate 
biological effective doses while without increasing toxicity. 
Here, we reported our 7-year experience of SBRT for 
localized prostate cancer. 
 
Material and Methods: Between November 2008 and Sep 
2013, a total of 135 patients with clinically localized prostate 
were enrolled for analysis. Patients were low-risk (19%), 
intermediate-risk (37%), and high-risk (44%). Low- and 
intermediate-risk patients were treated with SBRT alone 
(37.5Gy in 5 fractions). High-risk patients were treated with 
whole pelvic irradiation (45Gy in 25 fractions) and SBRT boost 
(21Gy in 3 fractions). All of intermediate- and high-risk 
patients received hormone therapy with different duration. 
The toxicities of gastrointestinal (GI) and genitourinary (GU) 
tracts were scored by Common Toxicity Criteria Adverse 
Effect (CTCAE v3.0). Biochemical failure was defined as 
Phoenix definition. 
 
Results: With a median follow-up of 52 months, there were 
seven patients with biochemical failure (one low-risk patient; 
one intermediate patient; five high-risk patients). The 
estimated 50-month biochemical failure-free survival (BFFS) 
was 95.8%, 96.4% and 81.5% for low-, intermediate, and high-
risk patients, respectively. In the high-risk group, there were 
two late biochemical failures around 60 months. In the SBRT 
alone group, acute Grade 3 GU and GI toxicities were seen in 
2.8% and 1.4% of the low/intermediate-risk patients, 
respectively; the incidence rate of late Grade 3 GU and GI 
toxicity were 3.5% and 0%. In the whole pelvic irradiation 
with SBRT boost group, acute Grade 2 GU and GI toxicity 
occurred in 31% and 21% of the high-risk patients, 
respectively; there was no grade 3 or higher late toxicity of 
GU and only one patient experienced grade 3 GI tract. Most 
of acute toxicity effects in the both groups resolved within 
three to six months of treatment completion. 
 
Conclusion: SBRT with or without whole pelvic irradiation for 
localized prostate cancer is feasible with minimal toxicity 
and encouraging biochemical failure-free survival but should 
be aware of late failure in the high-risk group. Use of whole 
pelvic irradiation for high-risk patients was not associated 
with higher GU or GI toxicity. Continued accrual and follow-
up would be necessary to confirm the biochemical control 
rate and the toxicity profiles. 
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Purpose or Objective: The definition of biochemical 
recurrence following radical prostatectomy for prostate 
cancer remains controversial in the era of ultrasensitive PSA. 
The AUA definition of PSA > 0.2 ng/mL may not be valid when 
PSA can be detected as low as 0.01 ng/mL. Randomized trials 
have shown a benefit in terms of biochemical progression-
free survival (bPFS) and metastasis free survival with 
adjuvant radiation compared to salvage but many patients 
enrolled as adjuvant actually had detectable PSA values. We 
compared patient outcomes with salvage radiotherapy based 
on pretreatment PSA in order to identify whether early 
salvage radiotherapy is more effective than treating later. 
 
Material and Methods: We performed an institutional review 
board-approved retrospective analysis of patients treated at 
our institution with post-prostatectomy image guided 
radiotherapy from 2005 to 2013. Patients with positive lymph 
nodes, those with an undetectable PSA and those with 
metastatic disease were excluded from our analysis. Data 
were abstracted from each patient’s electronic medical 
record including age, pathologic stage, Gleason score, margin 
status, androgen deprivation therapy, treatment to the 
pelvis, dose and PSA values. Patients were either treated 
with intensity modulated radiotherapy (IMRT) or volumetric 
arc therapy (VMAT) using daily image guidance. The use of 
ADT and the treatment of nodes was at the discretion of the 
treating physician. Radiation dose ranged from 6200-7400 
cGy. Post-salvage bRFS was defined as PSA < 0.4 ng/mL. 
Kaplan-Meier survival analysis was used to compare patients 
with a pre-RT PSA value ≤ 0.2 ng/mL to those with a value > 
0.2 ng/mL. Multivariate Cox regression analysis was used to 
evaluate significance of covariates on bPFS. 
 
Results: 196 patients staged N0 or Nx were treated with 
salvage RT after prostatectomy during the study period. 
Median pre-treatment PSA was 0.29 ng/mL; 117 patients had 
a PSA > 0.2 ng/mL and 79 ≤ 0.2 ng/mL. Median follow up 
time was 36 months, determined by the reverse Kaplan-Meier 
method. Overall comparison of the two groups showed that 
patients treated with a PSA < 0.2 ng/mL had significantly 
improved bPFS (p=0.003) and increased 36 month bPFS (76% 
vs 56%, p=0.0074) compared to those treated with higher PSA 
values (Figure 1). In multivariate analysis a pre-RT PSA > 0.2 
and increasing T stage and Gleason score were all 
significantly associated with worsening bPFS while positive 
margins were significant for improved bPFS (Table 1). Other 
covariates including treatment of nodes and use of ADT did 
not significantly influence bPFS following salvage. 
 
 
S44                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
 
 
 
Conclusion: Early post-prostatectomy salvage radiation 
before the PSA reaches 0.2 ng/mL results in superior bPFS 
compared to those treated later. This strongly suggests that a 
new definition of post-prostatectomy progression is needed. 
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I am honoured to have been invited to give this memorial 
lecture for which there are three main criteria: it is firstly to 
honour Emmanuel van der Scheuren, one of the fathers of our 
society. Secondly it aims to recognise scientific work within 
the field of radiation oncology and thirdly a contribution to 
education through the ESTRO programmes, in which I have 
been privileged to participate for the last 30 years or so. 
The first ESTRO annual conference was held in London in 
1982 and was memorable with the preparations being agreed 
between Emmanuel and Mike Peckham, my boss at the Royal 
Marsden Hospital at the time. I also want to acknowledge 
how dependent we were on many others for support, 
particularly among others for Lea, of whom we are thinking 
with gratitude especially at this time. 
 Scientific breakthroughs usually build on work that others 
have done and there are many examples from within the field 
of radiation oncology which I have experienced particularly in 
my area of research into whole-body irradiation. We work 
with the unchanging laws of physics but technology advances 
all the time and new biological understanding and new agents 
impact on the way in which we practice oncology. 
 I will discuss some of the ways in which progress in 
radiotherapy may occur and consider the factors which 
determine the impact of clinical trials, with particular 
reference to the START trials run by John Yarnold and his 
team. Consensus guidance, such as that contained in the 
ICRU report 50, has changed practice but there is still much 
evaluation work to be done in some areas. In our activity 
currently, process sometimes seems to take precedence over 
everything else, without the evaluation which would validate 
it.  
ESTRO’s contribution to education has been enormous and it 
has been exciting to be involved in the teaching courses and 
publications of ESTRO with its ever-changing and innovative 
approaches .It is good to note that a new era is starting for 
the School. Amongst all the changes in current practice the 
needs of individual patients must remain our priority 
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Do we need randomised clinical data to justify the use of 
SABR for primary and oligometastatic cancer? 
 
To be confirmed 
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Because the results obtained with stereotactic radiosurgery 
(SRS) and stereotactic ablative radiotherapy (SABR) have 
been impressive they have raised the question of whether 
classic radiobiological modeling are appropriate for large 
doses per fraction. In addition to objections to the LQ model, 
the possibility of additional biological effects resulting from 
endothelial cell damage and/or enhanced tumor immunity, 
have been raised to account for the success of SRS and SABR. 
However, the preclinical data demonstrate the following: 
1) Quantitative in vivo endpoints, including late responding 
damage to the rat spinal cord, acute damage to mouse skin 
and early and late damage to the murine small intestine, are 
consistent with the LQ model over a wide range of doses per 
fraction, including the data for single fractions of up to 20 
Gy. 
2) Data on the response of tumors to high single doses are 
consistent with cell killing at low doses. Thus the dose to 
control 50% of mouse tumors (the TCD50) can be predicted 
from cell survival curves at low doses and the number of 
clonogenic cells in the tumors. 
Further the clinical data show: 
3) The high local control of NSCLC and of brain metastases by 
SABR and SRS is the result of high radiation doses leading the 
high BED. In other words the high curability is predicted by 
current radiobiological modeling. 
4) Because high doses are required in SABR it is not possible 
to use it in all circumstances (e.g. for tumors close to critical 
normal structures). But because these high doses are needed 
Patient centric approach: myth or fact? 
